Department of Medical Sciences, Patras Highest Institute of Education and Technology, Patras, Greece.
Clin Ther. 2013 May;35(5):563-71. doi: 10.1016/j.clinthera.2013.02.022. Epub 2013 Mar 13.
When allergy or hypersensitivity and anaphylactic or anaphylactoid insults lead to cardiovascular symptoms and signs, including acute coronary events, the result might be the recently defined nosologic entity Kounis syndrome. Vasospastic allergic angina, allergic myocardial infarction, and stent thrombosis with occluding thrombus infiltrated by eosinophils and/or mast cells are the 3 reported variants of this syndrome.
The purpose of this review was to highlight and consolidate the recent literature on allergic angina and allergic myocardial infarction and to propose new therapeutic modalities for stabilizing mast cells.
A search for current literature on the pathophysiology, causality, clinical appearance, variance, prevention, and treatment of Kounis syndrome was conducted.
Kounis syndrome is caused by inflammatory mediators such as histamine; neutral proteases, including tryptase, chymase, and cathepsin-D; arachidonic acid products; platelet-activating factor; and a variety of cytokines and chemokines released during the mast-cell activation. Platelets with Fc γ receptor (FcγR) Ι, FcγRII, FcεRI, and FcεRII also have a role in the activation cascade. The same mediators released from the similar inflammatory cells are involved in acute coronary events of nonallergic etiology. These cells are not only present in the involved region before plaque erosion or rupture but also release their contents just before an acute coronary event. Pro-inflammatory mediators similar to those found in Kounis syndrome are found in some cases with nonallergic etiology, suggesting that this is a more general problem. The acute coronary and cerebrovascular events in Kounis syndrome may be prevented by the inhibition of mast-cell degranulation. Substances and natural molecules that protect the mast-cell surface and stabilize the mast-cell membrane are emerging as novel agents in the prevention of acute coronary and other arterial events.
The 3 reported variants of Kounis syndrome-vasospastic allergic angina, allergic myocardial infarction, and stent thrombosis with occluding thrombus-are caused by inflammatory mediators. Agents that inhibit mast-cell degranulation may be efficacious in preventing the acute coronary and cerebrovascular events of Kounis syndrome.
当过敏或超敏反应以及过敏样或类过敏刺激导致心血管症状和体征,包括急性冠状动脉事件时,其结果可能是最近定义的疾病实体 Kounis 综合征。血管痉挛性变应性心绞痛、变应性心肌梗死和支架内血栓形成伴阻塞性血栓中浸润的嗜酸性粒细胞和/或肥大细胞是该综合征的 3 种报告变体。
本综述的目的是强调和整合关于变应性心绞痛和变应性心肌梗死的最新文献,并提出稳定肥大细胞的新治疗方法。
对 Kounis 综合征的病理生理学、因果关系、临床表现、变异、预防和治疗的当前文献进行了搜索。
Kounis 综合征是由炎症介质引起的,如组胺;中性蛋白酶,包括类胰蛋白酶、糜蛋白酶和组织蛋白酶-D;花生四烯酸产物;血小板激活因子;以及肥大细胞活化过程中释放的各种细胞因子和趋化因子。具有 Fcγ 受体(FcγR)Ι、FcγRII、FcεRI 和 FcεRII 的血小板也在激活级联中发挥作用。在非变应性病因的急性冠状动脉事件中也涉及到从类似炎症细胞中释放的相同介质。这些细胞不仅存在于斑块侵蚀或破裂前的受累区域,而且在急性冠状动脉事件发生前释放其内容物。在一些非变应性病因的病例中发现了与 Kounis 综合征中发现的相似的促炎介质,这表明这是一个更普遍的问题。肥大细胞脱颗粒的抑制可能预防 Kounis 综合征中的急性冠状动脉和脑血管事件。保护肥大细胞膜并稳定肥大细胞膜的物质和天然分子作为预防急性冠状动脉和其他动脉事件的新型药物正在出现。
Kounis 综合征的 3 种报告变体-血管痉挛性变应性心绞痛、变应性心肌梗死和支架内血栓形成伴阻塞性血栓-是由炎症介质引起的。抑制肥大细胞脱颗粒的药物可能有效预防 Kounis 综合征的急性冠状动脉和脑血管事件。